The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer

Liu, Linjie; Teng, Jie; Zhang, Lijun; Cong, Peishan; Yao, Yuan; Sun, Gaofeng; Liu, Zhijun; Teng, Yuee; Liu, Mingjun

doi:10.1155/2017/2013989

Cited by 46 publications

(36 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Invasive methods can obtain relatively accurate pathological types; however, there are still cases of patient intolerance and complications. Previous studies 11,14,15 have demonstrated that serum tumour markers are valuable to differentiate histological types of lung cancer, but fewer studies 15,16 have showed the performance of spectral CT in evaluating lung cancer. Furthermore, there has not yet been a study showing the combined diagnostic efficiency of serum tumour markers and CT spectral parameters for lung cancer.…”

Section: Discussionmentioning

confidence: 99%

CT spectral parameters and serum tumour markers to differentiate histological types of cancer histology

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

CT spectral parameters and serum tumour markers to differentiate histological types of cancer histology

et al. 2018

View full text Add to dashboard Cite

show abstract

“…CK19 is mainly expressed in ductal epithelium (bile and pancreatic ducts, renal collecting ducts) and gastrointestinal epithelium [30]. Expression of CK19 might also be positive in pancreatic neuroendocrine tumours, hepatocellular cancer, cervical squamous cell cancer, thymic and lung cancers [31][32][33][34]. Malignant thyroid lesions present higher CK19 expression when compared to nonmalignant thyroid lesions [27].…”

Section: Discussionmentioning

confidence: 99%

The role of immunohistochemical examination in diagnosis of papillary thyroid cancer in struma ovarii

Szczepanek‐Parulska

Pioch

Cyrańska-Chyrek

et al. 2015

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Introduction. Struma ovarii (SO) is a monodermal teratoma in which thyroid tissue comprises more than 50% of the tumour. Papillary thyroid cancer (PTC) in SO is a rare finding, as only 5% of SO cases undergo malignant transformation. Malignant SO is usually asymptomatic and infrequently diagnosed preoperatively. Because of its rarity, there is no consensus about diagnosis and management, while treatment and follow-up procedures are not clearly established. Material and methods. Herewith, we report two cases of PTC in SO. The first patient was a 25-year-old woman diagnosed with bilateral ovarian tumours. The second patient, 19-year-old woman, presented with unilateral ovarian mass. Both patients were qualified for surgical excision of the tumours. Histopathological specimens underwent both conventional histopathological assessment and immunohistochemical staining. Results. In the first patient histopathology revealed SO with two foci of PTC. Immunohistochemically a positive expression of CK7, CK19, p63 and thyroglobulin (Tg) confirmed the diagnosis. She underwent total thyroidectomy in 2016 in order to enable ablative radioiodine therapy and facilitate further thyroglobulin monitoring. Unfortunately, the patient was lost from follow-up. In the second patient, histopathological diagnosis was follicular variant of PTC in SO. Postoperatively, a pelvic CT revealed osteolytic lesion 6 cm in size, being a metastatic change. The patient underwent unilateral ovariectomy, total thyroidectomy and multiple cycles of radioiodine therapy. Currently, 9 years following the diagnosis, the patient achieved disease remission. Conclusions. PTC in SO still remains a diagnostic and therapeutic challenge. Immunostaining for CK7, CK19, p63 and Tg might be helpful in histopathological diagnosis. The decision on the need of total thyroidectomy and radioiodine therapy should be made individually. However, thyroid remnant ablation increases the sensitivity and specificity of follow-up testing using serum Tg level as a tumour marker.

show abstract

“…Thirty patients with suspected advanced lung cancer who were unable to tolerate tissue biopsy (due to comorbidities or poor performance status) were screened for the study and subsequently enrolled. Inclusion criteria included patients with clinical symptoms suggestive of primary lung cancer or its distant metastasis; whole body PET‐CT with FDG‐avid lung mass with metastatic lesions in the mediastinum, contralateral lung, or distant organs; an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 3 or 4, a negative serum T‐SPOT ® (Oxford Immunotec Inc) test to rule out tuberculosis; and at least one elevated tumor marker out of a panel recommended by the Chinese guidelines for lung cancer diagnosis . Although patients were excluded from the study if they had primary co‐occurring malignancy, an occult malignancy could not be completely ruled out.…”

Section: Methodsmentioning

confidence: 99%

Detection of plasma EGFR mutations for personalized treatment of lung cancer patients without pathologic diagnosis

et al. 2020

View full text Add to dashboard Cite

Introduction Next‐generation sequencing (NGS) and digital polymerase chain reaction (PCR) based platforms have been used to detect EGFR mutations in plasma circulating tumor DNA (ctDNA) with high accuracy. Generally, molecular testing is performed after histopathological analysis. However, many patients with suspected advanced nonsmall cell lung cancer are unable to undergo biopsy thus forgoing potential treatment with highly effective tyrosine kinase inhibitors (TKIs) in patients with sensitizing EGFR mutations. We examined the utility of ctDNA testing to detect EGFR mutations in patients' plasma, where tissue biopsy is not feasible. Methods We conducted a single‐center, prospective study of 30 Chinese patients with suspected advanced lung cancer, who were unable to undergo a biopsy for initial diagnosis due to comorbidities or poor performance status. Patients with plasma EGFR sensitizing mutations were treated with first‐generation EGFR TKIs. Results Twenty of 30 patients enrolled had sensitizing EGFR mutations in ctDNA and were started on EGFR TKIs. After a median follow‐up of 12 months, median progression‐free survival (PFS) was 10 months and median overall survival (OS) was not reached. The median OS for the 10 untreated patients was 3 months. Conclusions In our study, patients with plasma EGFR mutations treated with TKIs showed disease control rate (DCR) and PFS similar to historical controls that were treated based on tissue testing. This is the first prospective study showing that ctDNA genotyping provides a feasible diagnostic approach for frail lung cancer patients who are unable to undergo biopsy, which subsequently leads to EGFR‐targeted therapy, and improved outcomes in this subgroup of patients.

show abstract

The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer

Cited by 46 publications

References 24 publications

CT spectral parameters and serum tumour markers to differentiate histological types of cancer histology

CT spectral parameters and serum tumour markers to differentiate histological types of cancer histology

The role of immunohistochemical examination in diagnosis of papillary thyroid cancer in struma ovarii

Detection of plasma EGFR mutations for personalized treatment of lung cancer patients without pathologic diagnosis

Contact Info

Product

Resources

About